Roxane Updated Launch Of Calcium Acetate Capsules
Last week, Roxane Laboratories, Inc. launched its calcium acetate capsules, 667mg. Since the October 15 exclusive launch of this product, Roxane Laboratories, Inc., has experienced tremendous demand.
Roxane Laboratories' calcium acetate capsules, 667mg are the only AB rated generic alternative to PhosLo (calcium acetate) capsules, used in the treatment of high levels of phosphate in patients with chronic renal failure. Annual sales of PhosLo (calcium acetate) capsules are approximately $84.8 million(1).
About Roxane Laboratories, Inc.
Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled release tablets; nasal sprays, cytotoxics and CII narcotics.
Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.